Abstract We report herein, two synthetic approaches to three types of nitrogen-containing bisphosphonates (N-BPs) in moderate to high yields (58-88%). Ester cleavage of selected bisphosphonates was undertaken to obtain their N-BP-acid analogs. Based on the reported bisphosphonate properties and the prospective biological prediction using computer-assisted molecular modeling (CAMM), new compounds were evaluated in a mouse model of antigen-induced arthritis (AIA) and the delayed-type hypersensitivity granuloma reaction (DTH-GRA) for chronic inflammation. Pharmacological results showed that N-BP-acids are more favorable for antiarthritis activity than N-BP-esters. On the other hand, the majority of N-BPs revealed good antiinflammatory potency compared to their acid analogs. The results also showed that the presence of a free thiol group in a molecule enhances the anti-inflammatory activity. Furthermore, bioscreening results were in good agreement with the prediction investigation. A hypothesis of molecular modeling study, including fitting of the synthesized compounds into 3D-pharmacophore using Discovery Studio 2.5 software and their docking into the human farnesyl pyrophosphate synthase (hFPPS, PDB code: 2F8C protein) showed good results consistent with the observed pharmacological properties. 
Introduction
Bisphosphonates (BPs) are synthetic pyrophosphate mimics, which have been developed and used for the treatment of bone diseases (Fig. 1 , Emesto et al., 2007) . The pronounced selective activity of BPs for bone tissues gives them a key advantage in clinical practice and the mainstay of antiresorptive therapy for osteoporosis (Balakrishna et al., 2011; Emesto et al., 2007; Fleisch, 1988 Fleisch, , 1995 . BPs inhibit bone resorption by reducing osteoclast activity and inducing osteoclast apoptosis (Balakrishna et al., 2011; Fleisch, 1995 Fleisch, , 1988 . They are therefore, used for treatment post-menopausal osteoporosis in women and reducing the associated bone fracture risk (Cheng and Oldfield, 2004) .
Nitrogen-containing bisphosphonates are known as the second generation of BPs and are proven to be more effective. These drugs are used in diverse therapeutic areas such as microbial (Wang et al., 2001) , parasitic (Docampo and Moreno, 2001) , herbicidal (Cromartie et al., 1999) , viral (HIV) (Mckenna et al., 1999) , cancer diseases (Fleisch, 2002; Senaratne and Colston, 2002) as well as chronic inflammation and arthritis (Francis et al., 1989; Nugent et al., 1993; Ö sterman et al., 1997) . The activity of N-BPs has accounted to their effect on human farnesyl (hFPP)-and human geranyl geranyl pyrophosphate synthase (hGGPP), which are enzymes in the mevalonate pathway, decreasing the prenylation of essential GTP-binding proteins (Dunford et al., 2006) . Furthermore, it is well established that N-BPs bearing free amine group (or alkylated amine, known as the third generation of BPs) at one of the side chains are usually preferable in clinical use because of their higher potency (Bijvoet et al., 1995) .
In human rheumatoid arthritis (RA), osteoclasts are found at sites of tissues invasion and emerge from synovial inflammatory tissues (Hannig et al., 2007; Ö sterman et al., 1997) , therefore, inhibition of osteoclastogenesis is a powerful approach to prevent arthritic bone destruction (Hannig et al., 2007) . As a part of our ongoing research program on the applications of BPs in pharmacology (Abdou et al., 2014 (Abdou et al., , 2012b Kamel et al., 2012; Shaddy et al., 2013) , we herein, accomplished a synthesis of a variety of b-aminobisphosphonates and their relevant bisphosphonic acids. New compounds were examined vs RA in animal antigen-induced arthritis (AIA) and for the chronic inflammation in animal model of the delayed-type hypersensitivity granuloma reaction (DTH-GRA). The optimized antiarthritis/antiinflammatory activities of synthesized N-BPs and N-BP-acids are also based on the prospective predicted potency, using the computer-assisted molecular modeling (CAMM) (Da Silva et al., 2010; Lagunin et al., 2003) . Later, a hypothesis of molecular modeling study, including fitting of the synthesized compounds into 3D-pharmacophore using Discovery Studio 2.5 software (Girgis et al., 2011; Shahin et al., 2014) and their docking into the human farnesyl pyrophosphate synthase (hFPPS, PDB code: 2F8C protein) showed good results consistent with the observed pharmacological properties.
Material and methods

General data
Melting points were determined with open capillary tube on an Electrothermal (variable heater) melting point apparatus and were not corrected. IR spectra were recorded on a JASCO FT-IR 6100 using KBr disk (JASCO, Japan). NMR spectra were measured with a JEOL E.C.A-500 MHz ( 13 C: 125.7 MHz, 1 H: 500 MHz, 31 P: 202.4 MHz) spectrometer (JEOL, Japan).
31 P NMR spectra were recorded with H 3 PO 4 (85%) as external reference. 1 H and 13 C NMR spectra were recorded with trimethylsilane as internal standard in CDCl 3 . Chemical shifts (d) are given in ppm. The mass spectra were performed at 70 eV on an MS-50 Kratos (A.E.I.) spectrometer provided with a data system spectrometer (Kratos, UK). Elemental analyses were carried out at the Microanalysis Laboratory, Cairo University, Cairo, Egypt, using elementary Analysen-systeme GmbH-vario EL III Element Analyzer, Germany. The appropriate precautions in handling moisture-sensitive compounds were observed. The purity of all new samples was verified by microchemical analysis (C/H/N/S) and spectroscopy. Solvents were dried by standard techniques. Thin-layer chromatography (TLC): Merck 0.2 mm silica gel 60 F254 analytic aluminum plates. All international principles and local regulations concerning the care and the use of laboratory animals were considered during the pharmacological screening. The azide 2 was prepared according to the reported method (Pokhodylo et al., 2010) . (3-amino-4,5,6,7-tetrahydro-2H [1] benzothieno [2,3-b] pyrrole-2,2-diyl)bisphosphonate (4) for C 13 H 10 N 6 O 2 (282.26): C, 55.32; H, 3.57; N, 29.77. Found: C, 55.39; H, 3.43; N, 29.64 .
Preparation of tetraethyl
Preparation of ethyl
Following the previous procedure described for the synthesis of compound 4 and using the same amounts, the azide 6 (0.8 g, 3 mmol) reacted with 1 (0.9 g, 3.2 mmol) in EtONa (80 mg, 3.5 mmol) solution at r.t. for 6 h. The product mixture was cooled, poured into iced water, and acidified with conc HCl, followed by extraction with AcOEt, dried, and the volatile materials were removed under reduced pressure until dryness. Crystallization of the resulting residue from CHCl 3 afforded the bisphosphonate 7 as pale yellow crystals. Yield: 
Preparation of nitrogen-bisphosphonates (N-BPs, 11a-d)
Step 1: to a solution of azide 6 (2.82 g, 10 mmol) in CH 2 Cl 2 (10 mL), triphenylphosphine (PPh 3 ) (3.27 g, 12.5 mmol) in CH 2 Cl 2 (10 mL) was added. The reaction mixture was stirred at r.t. for 6 h and the volatile materials were removed under vacuum. The precipitated material was collected (4.65 g, 90.2%), washed with ligroin to give the iminophosphorane (A) as colorless material in 90.2% yield (Abdou et al., 2012a) . Compound A is pure enough and stable for few days at À10°C;
Step 2: to a solution of A (1.29 g, 2.5 mmol) in THF (15 mL), methyl-, ethyl-, phenyl-, and/or cyclohexaneisocyanate (9a-d, 2.5 mmol) were added at r.t. After the mixture was stirred for %8 h (TLC) at 0 to À5°C, the solvent was distilled off in vacuum, and the residue was washed thoroughly with ether/petroleum ether (1:2, 20 mL) to get rid of Ph 3 PO, yielding the carbodiimides 10. Compounds 10a-d (%80%) were generally used directly without further purification;
Step 3: to the in situ carbodiimides 10a-d (2 mmol), phosphoryl carbanion 1 (0.69 g, 2.4 mmol) in EtONa solution (64 mg Na, 2.8 mmol/20 mL EtOH) was added in one portion, and the mixture was further stirred at r.t. for %8-10 h (TLC). The product mixture was cooled-up, poured into iced water, and acidified with conc HCl, followed by extraction with AcOEt, dried, and the volatile materials were removed under reduced pressure until dryness. The resulting residue was crystallized from the proper solvent to give the bisphosphonates 11a-d. 
Preparation of nitrogen-bisphosphonates 16a-d
A mixture of 2-aminobenzenethiol (13) (1.25 g, 10 mmol) and aldehyde: 4-(dimethylamino)-, 4-hydroxy-, 2-hydroxy-, or 4-methoxy-benzaldehyde 14a-d (10 mmol) in EtOH (20 mL) containing AcOH (1 mL) was stirred under reflux for %3 h (TLC). The resulting Schiff-bases 15a-d were precipitated and allowed to react in situ with 1. Phosphoryl carbanion 1 (1.2 g, 4.2 mmol) in DMF (20 mL) containing LiH (0.1 g, 12.6 mmol) was added under stirring to the substrates 15a-d (3.5 mmol). The suspension was stirred at r.t. for further 30 min and then heated under reflux for the appropriate time %18 h (TLC). The product mixture was cooled-up, poured into iced water, and acidified with conc HCl, followed by extraction with AcOEt, dried, and the volatile materials were removed under reduced pressure until dryness. The resulting residue was crystallized from the proper solvent to give the bisphosphonates 16a-d. According to the reported method by Nugent et al. (1993) , groups of 6 female albino mice, 6-8 weeks of age, were immunized subcutaneously (sc) with an emulsion of methylated bovine serum albumin (mBSA) and Freund's complete adjuvant supplemented with extra heat killed M-tuberculosis. Secondary immunizations were performed after 7 days, and after a further 14 days the animals were challenged intraarticularly with 200 mg of mBSA in saline into the left rear stifle joint. The tested compounds 4, 5A, 7, 8A, 11a,b, 12aA, 16a,b, and 17aA,bA as well as the positive control, N-BP-drug (zoledronic acid, Zol) 18 were dissolved, suspended, or emulsified in sterile saline and sonicated where appropriate to homogeneous doses. All compounds were then adjusted to pH 7.0 with 0.1 M NaOH and stored frozen in aliquots. Fresh aliquots were used for each day of dosing. Mice were dosed sc in the scruff of the neck from the day of intraarticular mBSA challenge (day 0) using a 5 of 7 day dosing regimen until the conclusion of the study on day 28. The mBSA-injected stifle joint was then skimmed, removed, and fixed in phosphatebuffered formaldehyde solution prior to decalcification and histological preparation. The assessment of arthritis was performed on sagittal joint sections stained with hematoxylin and eosin. Sections were graded 1 (mild) to 5 (severe) for soft tissue inflammation, pannus formation, and extent to cartilage and bone erosion. The changes (DPV) which occurred in the arthritic control and treated rats (injected and noninjectedmBSA) were quantitated on day 28 by mercury displacement plethysmography. The component scores were summed to give arthritis score. Statistical comparisons were performed by one-way analysis of variance (ANOVA), compared with vehicle-treated control. Resulted data are displayed in Table 1 .
Delayed-type hypersensitivity granuloma
According to the reported methods by Nugent et al. (1993) and Ö sterman et al. (1997) , groups of 6 female albino mice (25-30 g) were sensitized with an emulsion of methylated bovine serum albumin (mBSA) and Freund's incomplete adjuvant and dextran by sc injection over the inguinal lymph node. Three weeks later, hydroxyapatite (HA) disks (6 mm diameter) soaked in mBSA solution (30 mg/mL saline) were implanted sc in dorsum of the mice (two disks, bilaterally). All tested compounds (4, 5A, 7, 8A, 11a-d, 12aA, 12bA, 16a-d, 17aA, 17bA , and ZometaÒ) were prepared as solutions, suspensions, or emulsion in sterile saline and sonicated where appropriate to homogeneous doses, and the pH was adjusted to 7.4 with 0.1 M NaOH. Each mouse received compound in a volume of 0.1 mL/10 g body weight sc in the scruff of the neck. Dosing commenced on the day of implantation of the mBSA soaked disks and was continued thereafter on a daily basis until day nine, when the mice were euthanized. The granulomatous lesions were then excised and both wet and dry tissue weights measured. Results were analyzed by students paired test. Resulted data are displayed in Table 2 . Potency of the tested compounds was calculated regarding zoledronic acid, reference standard according to the following equation:
%Potency ¼ Group% edema inhibition of tested compound Group% edema inhibition of zoledronic acid 2.8.3. Toxicity evaluation of promised BP-derivatives 7, 16a, and 17bA
The LD 50 determination of the most promising synthesized and antiinflammatory active agents (7, 16a, and 17bA) was carried out by the standard known LD 50 method in mice (Ka¨rber, 1931) . Albino mice weighing 20-25 g were divided into six groups of six mice each. Administrations of the tested compounds dissolved in the same vehicle solution in 500, 750, and 1000 mg/kg (body weight) were given intraperitoneally. Control groups were given in buffer solution only. Toxic symptoms, mortality rates, and postmortem findings in each group were recorded 24 h post administration. LD 50 of the tested compounds were calculated according to the following formula:
where D m is the largest dose, which kills all animals, z is the mean of dead animals between two successive doses, d = the constant factor between two successive doses, n is the number of animals in each group, R is the sum of (z Â d). 
Chemistry and results of biological studies
Chemistry
We adopted two different protocols for synthesis of our targets, N-BPs: (i) consisted of coupling azido-substrates with the phosphorus reagent, tetraethyl methylenebisphosphonate (1)/catalyzed by sodium ethanolate (EtONa); (ii) involved one-pot three-component synthesis, by applying 1 in an alkaline solution to carbodiimide-or Schiff-base derivatives, initially generated in situ.
Schemes 1 and 2 describe synthesis of b-amino-BPs 4, 7 and their acid analogs 5 and 8 from the coupling condensation of 1 with the azides 2 and 6. When the azide 2 (Pokhodylo et al., 2010) was caused to react with slight excess of phosphonyl carbanion 1 in EtONa solution, tetraethyl (3-amino-4,5,6, 7-tetrahydro-2H-[1]benzothieno-[2,3-b]pyrrole-2,2-diyl)bispho sphonate (4) was isolated in 87.6% yield. As the pharma laboratories proved remarkable therapeutic value of BP-acids than BP-esters (Fleisch, 1995 (Fleisch, , 1988 , hydrolysis of 4 to the corresponding acid 5 was undertaken using trimethylsilyl bromide (TMS-Br) in chloroform, followed by quenching with water. The resulted acid 5 is hygroscopic and can be kept only under vacuum for identification purposes. Later on, it was stirred in a solution of aqueous NaOH (10%/Methanol, 20 mL (1:3 v/v) for 1 h, followed by concentration to give its disodium salt 5A (Nugent et al., 1993; Zhou et al., 2014 ) (Scheme 1).
The IR (t max/ cm
À1
) spectrum of N-BP 4 revealed the lack of the azido-and the nitrile groups and revealed the presence of stretching frequencies at 3441-3333 (NH 2 ), P‚O (1254, free), 1234 (P‚O, H-bonded, due to its H-bonding with one proton of the amino group), and at 1075, 1029 (PAOAC). In this context, the NH 2 -protons were displayed in the 
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Vepsaelaeinen, 2008). As displayed in Scheme 1, the azides smoothly react with the reagent 1 in refluxing ethanol with the evolution of nitrogen to yield the intermediate 3 (Deep et al., 1991; Cadogan et al., 1978) . Further reduction of the cyano group and intramolecular cyclization led to the product 4. The hydrolysis of the nitrile group was observed due to the presence of the alkaline medium and the heating. Similarly, the fused pyrrole-2,2-diylbisphosphonate 7 was synthesized in 84.8% yield by treating ethyl 4-azido-5-cyano-1-phenyl-1H-pyrazole-3-carboxylate (6) with the phosphorus reagent 1 in EtONa solution at r.t. under the same reaction conditions. It is notable to mention that the azide 6 was prepared and identified for the first time. Compound 7 underwent ester cleavage as previously mentioned to give 8, followed by its conversion to its disodium salt 8A. The 1 H-, 13 P-, and 13 C NMR data of 7 and 8 are consistent with the assigned structures (see the experimental section) (Scheme 2).
Next, one-pot three-component reactions were applied for the synthesis of N-BPs 11a-d and relevant N-BP-acids 12a,b (Scheme 3). The first step of the process involved the iminophosphorane (A) formation (90%) from the reaction of the azide 6 with Ph 3 P in CH 2 Cl 2 . The precipitated phosphorane (A) was treated with a proper isocyanate 9a-d in tetrahydrofuran (THF) to give the required carbodiimides 10a-d in >80% yields via the aza-Wittig reaction. NHeterocumulenes 10a-d were highly unstable, and should be quickly freed from Ph 3 PO, and could be kept at À5 to 0°C for few days (Liu et al., 2008; Abdou et al., 2013) . Further addition of ethanolate solution of phosphonyl carbanion 1 to 10a-d afforded the target fused pyridine-3,3-diyl-bisphospho nates 11a-d in 62-74% yields. 11a,b underwent ester cleavage as previously described to afford the respective acids 12a, 12b followed by their disodium salts 12aA and 12bA (Scheme 3).
The In another type of multi component reaction (MCR), the Schiff-base intermediates 15 generated in situ from 2-aminobenzenethiol (13) and the proper aldehyde 14a-d were trapped by phosphoryl carbanion 1 in DMF solution containing lithium hydride (LiH) (Keglevich and Ba´lint, 2012; Li et al., 2014) . After the working up, N-BPs 16a-d were obtained in 58-68% yields, via the addition reaction at the exocyclic imines. N-BPs 16a,b underwent ester cleavage using TMSBr, as previously mentioned to afford the respective acids 17a, 17b followed by conversion to their disodium salts 17aA and 17bA (Scheme 4).
In the IR (t max , cm
À1
) spectra of 16a-d showed the NH band the range 3433-3357 and the SH moiety at %2558 (free thiol), the two P‚O bands within the range 1262-1254 (free) and 1242-1228 (H-bonded). 
Pharmacology
Bisphosphonates (BPs) have been proven to be an important asset in the treatment and prevention of bone resorption and osteoporosis (Fleisch, 1995 (Fleisch, , 1988 Balakrishna et al., 2011) . However, they seem to have different effect on hypocalcemia resulted from diseases such as tumor-induced osteolytic bone diseases, chronic inflammation, and human arthritis (Balakrishna et al., 2011) . 
Biological activity spectra prediction
Elaborating a new entity in drug discovery needs optimization: Data Base, permeability, and Computer Assisted Programs are used for this purpose. PASS program is an important tool to be used for designing in drug discovery. Prospective biological activity spectra of the molecular structures of synthesized NBPs 4, 7, 11a-d, 16a-d, and N-BP-acids 5, 8, 12a,b, 17a,b, starting materials 2 and 6 as well as the reference drug zol-18 were predicted in the early stage of the investigation. The computer-assisted molecular modeling (CAMM) program: PASS program 2012.1 version (IBMC, Moscow, Russia) was adopted for designing -in silico -the potential structures (Da Silva et al., 2010; Lagunin et al., 2003) . Data of the PASS results were presented as a list of activities (supplementary materials, appendix 1). The study indicated that the main expected biological activity of the designed compounds was the antiosteoarthritic and antiinflammation potencies as common properties among these compounds. Furthermore, the results demonstrated that structures 7, 8, 16a, 16b, 16d, and 17b are the most molecules of potential efficacy while compounds 4, 11a, 11b, 12b, and 16c showed moderate activity. On the other hand, BP-derivatives 2, 5, 6, 11c, 11d, 12a, and 17a displayed only weak potency.
Bioassays
The articular pathology of antigen-induced arthritis (AIA) (Nugent et al., 1993; Ö sterman et al., 1997) involves an initial intense inflammatory synovitis followed by chronic inflammation and severe erosion of articular cartilage and subchondral bone resembling human rheumatoid arthritis (RA) (Nugent et al., 1993; Brackertz et al., 1977) . Both the synovitis and joint destruction are unaffected by non-steroidal antiinflammatory drugs (NSAID) (Nugent et al., 1993) but can be suppressed by corticosteroids such as dexamethasone.
The delayed type hypersensitivity granuloma assay is a model of chronic inflammation, in which mice were previously sensitized to methylated bovine serum albumin (mBSA) and surgically implanted with hydroxyapatite disks (two per mouse) soaked in mBSA in order to generate granulomas. This model is not affected by tradition NSAID such as indomethancin (Nugent et al., 1993) . However, the antiarthritic properties of bisphosphonic acids (BPs) are poorly understood and have not been demonstrated in any other models of arthritis (Markusse et al., 1990) . Furthermore, the antiinflammatory potential of BP-acids has been largely ignored (Daoud et al., 1987; Hyvonen and Kowolik, 1992) .
Another article reported that may be BPs and BP-acids take different pathways (Nugent et al., 1993) .
Antiarthritis
The antiarthritic assay result was displayed in Table 1 . Data reflected the effects of sc administered selective six out of 10 new N-BPs, 4, 7, 11a,b, 16a,b and five out 6 new N-BP-acid salts, 5A, 8A, 12aA, 17aA and 17bA on AIA in a mouse model over 28 days. ZometaÒ (18, zoledronic acid, Fig. 2) , which is N-BP-acid drug was used as a positive control since it revealed an activity against RA (Dunn et al., 1990) . In our experiments, 18 (dose: 30-200 mg/kg) exerted significant inhibitory effects on the arthritis, and in general the tested compounds displayed a moderate to good activity in the same dose range as 18. These exceptions were 17aA, 17bA (N-BP-acid salts), which showed higher inhibition (p < 0.001) at 40-200 mg/kg. Compound 8 also displayed a significant inhibition (p < 0.001) at 30-200 at a slightly higher range (100-200 mg/kg). The NBPs 7, 16a, 16b, and 11a revealed an excellent inhibition (p < 0.001) at 60-200 mg/kg whereas they showed only a marginal activity at a higher dose (100 mg/kg). Finally, compound 11b displayed a good activity at 100 mg/kg, while 4, 5A showed only a marginal one at 100-200 mg/kg, which is not statistically remarkable. 
Antiinflammatory, DTH-GRA biological evaluation
The previous eleven compounds and others (all sixteen new compounds) were profiled in a delayed-type hypersensitivity granuloma model (Nugent et al., 1993 ). Thus, the tested compounds 4, 5A, 7, 8A, 11a-d, 12aA,bA, 16a-d, and 17aA,bA as well as the positive control ZometaÒ 18 administered sc, and the results were displayed in Table 2 . Compound 18 reproducibly inhibited granuloma wet and dry weights. Bisphosphonate esters 7, 16a and 16b significantly inhibited (higher than the positive control) the granuloma in a dose-dependent manner at the doses examined (25-100 mg/kg), while the esters 11a, b and 16c,d exerted significant inhibition, which were almost equivalent to that of 18 over the same dose, at 100 mg/kg. Others 4, 11c,d displayed moderate activity against dry/wet granuloma and were not dose related. In contrast, the acid salts 5A, 8A, 12aA,bA and 17aA,bA, all showed dramatic drop in the activity in relative to their phosphonate ester analogs against the dry/wet weight granuloma.
The structure activity correlation based on the obtained results in Tables 1 and 2 indicates that bisphosphonate esters 7, 16a, 16b showed an excellent efficacy in both models. However, the inhibition of DTH-GRA was not always predictive of the activity of the BPs in the AIA models, suggesting that anti arthritis/antiinflammatory activity may involve more than one mechanism that the effect of BPs as anti-inflammatory is better than the parallel BP-acids (Nugent et al., 1993) . In favor of this suggestion speaks the fact that while some BP-acid salts 8A, 17aA and 17bA demonstrated excellent antiarthritic properties, these acids showed only moderate antiinflammatory potential. The fact that S,N-BPs 16a-d induce significant antiinflammatory property implies that the presence of a free thiol moiety enhances the antiinflammatory efficacy of these compounds (Abdou et al., 2006; Almstead et al., 1999; Cawston, 1996; Siestema and Ebetino, 1994) . Furthermore, this result probably (suggested by the referee) should be due to the different lipophilicity, and permeability, of the esters with respect to the acids. Probably the esters were hydrolyzed in vivo with different time, and in the arthritic test that was performed in 28 days with somministration after 5 or 7 days the difference between the acids and the esters is reduced with respect to the anti-inflammatory test, that was performed in 9 days with a daily somministration. At this point, the comparison of the activity of NBPS with NBP-acids is not completely correct.
Furthermore, the analysis of the biological activity spectra prediction of the new compounds made in this publication is a good example of in silico study of chemical compounds before their experimental investigations. The analysis was performed using the free available web site with the internet version of PASS and PharmaExpert: http://www.ibmc.msk.ru/PASS (CAMM) (Da Silva et al., 2010; Lagunin et al., 2003) . The spectrum for a substance is a list of the biological activity types for which the probability to be revealed (Pa) and the probability not to be revealed (Pi) are calculated. Pa and Pi values are independent and their values vary from 0 to 1 (supplementary material, appendix 1). By default, in PASS Pa = Pi value is chosen as a threshold, therefore all compounds with Pa > Pi are suggested to be active. Correlation between the results of the computer-assisted prediction and the in vivo pharmacological results is demonstrated in Table 3 .
Toxicity of the promised products
Toxicological study of the most promising synthesized active compounds 7, 16a and 17bA was performed using medium lethal dose 50% (LD 50 ) standard method (Ka¨rber, 1931) in mice in 500, 750, and 1000 mg/kg (body weight), i.e. $5 folds of the used antiarthritis and antiinflammatory effective doses. However, no toxic symptoms or mortality rates were observed after 24 h post administrations explaining the safe behavior of the used doses.
Molecular modeling docking studies
Molecular docking of the new bisphosphonate esters (N-BPs) 4, 7, 8, 12a, b, 17a, b , and the reference drug zoledronic acid (Zol, 18) into the human farnesyl pyrophosphate synthase (hFPPS, PDB code: 2F8C protein) (Rondeau et al., 2006) was performed using the Accelrys Discovery Studio 2.5 modules (Girgis et al., 2011; Shahin et al., 2014) . The results are displayed in Table 4 .
Considering N-BP-acids, except 5, BP-acids 8, 17a,b showed markedly higher docking scores than the reference drug 18 while 12a,b showed close docking scores to 18. On the other hand, all N-BPs indicated lower scores than the same reference. Description of the binding sites of interactions between these most active molecules 8, 17a, 17b and the enzyme in comparison with the reference drug 18 is recorded in Fig. 3 . The binding interaction forces of the lead compound 18 at the binding sites showed 6H-bonds with the amino acids # Arg 112 (2 HB), Asp 103 (3 HB), and Asp 107 (1 HB), but didn't show p-p interactions; the Cdock score = À49.67 kcal/ mol. This assumes that the interaction of the reference 18 with these three amino acids is essential for the activity and that they represent the catalytic triad of such enzyme. Concerning our tested molecules, compound 17b showed docking score = À53.41 kcal/mol, and 8 HB with Arg 112 (2 HB), Asp 103 (3 HB), Asp 107 (2 HB) and Gln 96 (1 HB). Compound 17a showed docking score = À50.85 kcal/mol and 7 HB with Arg 112 (1 HB), Asp 103 (2 HB), Asp 107 (2 HB), Asp 174 (1 HB) and Gln 96 (1 HB). In addition, compound 8 showed docking score (À50.00 kcal/mol) with 3 HB at the same triad [Asp 103 (2 HB), and Asp 107 (1 HB) and one pp interaction with Arg 112]. These data are predicting that N-BP-acids have the same mode of action like the reference drug 18, but with higher efficacy as inhibitor for FPPS enzyme and slightly higher activity. While compound 12b showed nearly similar docking score (À49.81 kcal/mol) in comparison with 18, with 5 HB at the same catalytic triad [Arg 112 (2 HB), Asp 103 (2 HB), and Asp 107 (1 HB), and one p-p interaction with Arg 60].
On the other hand, the prepared ester bisphosphonates 4, 6, 11a-d, 16a-d showed lower docking scores and fewer number of H-bonding than the reference drug 18, as shown in Table 4 . The data also indicate that these compounds have less inhibitory activity for FPPS enzyme. 3.2.7. Correlation between molecular docking studies and antiarithritic-DTH-GRA biological evaluation
Since the inhibition of FPPS enzyme is an important step in the inhibition of osteoclastic activity, it is now widely used as an approach for preventing the bone loss associated with osteoporosis and antiarthritis activity. In this study, we found that the acids 17a,b, 12a,b, and 8 that showed significant docking scores and high numbers of binding-site interactions at the hFPPS enzyme have the highest antiarithritic activity among all the tested compounds and the reference drug 18. The bisphosphonate molecules (4, 7, 11a-d, 16a-d) that showed less docking scores and fewer number of binding-site interactions with hFPPS, also showed lower antiarithritic activity (Tables 1 and 4 ). The above conclusion indicated that the correlation between the virtual docking scores and the biological activities are closely matching to each other.
Conclusion
In summary, efficient and useful two synthetic protocols were applied to construct under mild conditions, various b-aminomethylene-1,1-bi sphosphonates (N-BPs) in good to excellent yields (58-88%). We attempted in this research work to utilize the high bone specificity of the third generation of N-BPs that contain primary amine group as one of the side chain (Bijvoet et al., 1995) to elaborate new entities for treating rheumatoid arthritis and chronic inflammation. Other elements such as chemical moieties of potential anticatabolic activities, e.g., the pyrrol and/or pyridine nucleus as well as the biological activity spectra prediction using CAMM programs were also considered. The obtained results indicated that three new BPs have antiarthritic/antiin flammation activities higher than the positive control (BP-drug) at the same doses. These three BP-acids have either free thiol and/or free amino side chain groups. These groups may facilitate the binding to the metal atom in the active site of the matrix metalloproteinases (MMPs) (Almstead et al., 1999; Balakrishna et al., 2011; Cawston, 1996; Cheng and Oldfield, 2004) . Finally, from previous (Barbier et al., 1986; Hannig et al., 2007; Nugent et al., 1993) and present studies, it is concluded that osteoclast activity plays an important role in bone loss in rheumatoid arthritis (RA). This suggests that osteoclasttargeted therapies may effectively prevent skeletal damage in patients with RA. Furthermore, docking studies for new compounds were performed in order to explore their possible binding mode at hFPPS, PDB code: 2F8C.
